Orthofix Medical Inc. (NASDAQ:OFIX) is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.36 per share.
For the full year, analysts predict revenues of $ 374.30 million, while looking forward to loss of $ 0.38 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 467.00 million ~ $ 477.00 million, where as bottomline are predicted in a range of $ 1.00 ~ $ 1.10 per share
Click Here For More Historical Outlooks Of Orthofix Medical Inc.
Previous Quarter Performance
Orthofix Medical Inc. disclosed loss for the second quarter of $ 0.59 per share, from the revenue of $ 73.14 million. The quarterly revenues reduced 36.87 percent compared with the same quarter last year. Wall street analysts are predicting, OFIX to report 2Q20 loss of $ 1.08 per share from revenue of $ 50.74 million. The bottom line results beat street analysts by $ 0.49 or 45.37 percent, at the same time, top line results outshined analysts by $ 22.40 million or 44.15 percent.
Stock Performance
Shares of Orthofix Medical Inc. traded up $ 0.83 or 2.54 percent on Wednesday, reaching $ 33.48 with volume of 129.30 thousand shares. Orthofix Medical Inc. has traded high as $ 33.65 and has cracked $ 32.42 on the downward trend
The closing price of $ 33.48, representing a 47.67 % increase from the 52 week low of $ 22.11 and a 31.85 % decrease over the 52 week high of $ 47.91.
The company has a market capital of $ 647.08 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
Orthofix Medical Inc. will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.orthofix.com
Orthofix Medical Inc., a medical device company, provides musculoskeletal healing products and therapies worldwide. It operates through four segments: Bone Growth Therapies, Spinal Implants, Biologics, and Orthofix Extremities. The Bone Growth Therapies segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spinal appendicular fractures.
